| 常晋霞,李兴妍,刘文虎.曲妥珠单抗获得性耐药机制及应对策略[J].中国肿瘤,2018,27(4):299-305. |
| 曲妥珠单抗获得性耐药机制及应对策略 |
| Acquired Trastuzumab Resistance：Mechanisms and Coping Strategies |
| 投稿时间：2018-01-24 |
| DOI：10.11735/j.issn.1004-0242.2018.04.A010 |
|
 |
| 中文关键词: 曲妥珠单抗 HER2 获得性耐药 |
| 英文关键词:rastuzumab HER2 acquired resistance |
| 基金项目: |
|
| 摘要点击次数: 2409 |
| 全文下载次数: 774 |
| 中文摘要: |
| 摘 要：曲妥珠单抗是靶向人表皮生长因子2(HER2)的单克隆抗体药物，对HER2表达阳性乳腺癌及胃癌治疗效果确切。然而多数患者在用药1年内出现了获得性耐药，导致其疗效降低甚至无效。研究表明，信号通路异常激活；表皮生长因子受体(EGFR)及其配体异常表达及肿瘤诱发上皮—间质转化(EMT)均可成为曲妥珠单抗耐药的重要机制，联合使用PI3K/AKT/mTOR通路抑制剂及其相关生存信号通路抑制剂可逆转曲妥珠单抗耐药。本文就曲妥珠单抗耐药机制及逆转耐药策略进行综述。 |
| 英文摘要: |
| Abstract：Trastuzumab，a monoclonal antibody targeting the human epidermal factor 2（HER2），has proven to have a reliable therapeutic effect on HER2-positive breast and gastric cancer. However，the acquired resistance would occur within one year of treatment in majority of patients. As a consequence，the effect dropped even down to zero. The studies have shown that aberrant activation of signaling pathways，abnormal expression of epidermal growth factor receptor（EGFR）and its ligand，and cancer-induced epithelial-mesenchymal transition（EMT） are possibly the mechanisms of trastuzumab resistance. Therefore，combination of PI3K/AKT/mTOR pathway inhibitors and inhibitors to other relevant survival signaling pathways may reverse trastuzumab resistance. In this article，we discuss and summarize the mechanisms of trastuzumab resistance and the coping strategies. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|